Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 443-452

  Pantaleo, Maria A ^a   Nannini, M ^a   Lopci, E ^b   Castelucci, P ^b   Maleddu, A ^a   Lodi, F ^a   Nanni, C ^b   Allegri, V ^b   Astorino, M ^a   Brandi, G ^a   Di Battista, M ^a   Boschi, S ^a   Fanti, S ^b   Biasco, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

11C choline PET; 11C methionine PET; 68Ga DOTA NOC PET; Bevacizumab; PET; Response evaluation criteria in solid tumors; Sunitinib

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 NAL3 OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] GA 68; ACETIC ACID C 11; BEVACIZUMAB; CHOLINE C 11; DOCETAXEL; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUOROTHYMIDINE F 18; FLUOROURACIL; FOLINIC ACID; GALLIUM 68; IRINOTECAN; METHIONINE C 11; NEW DRUG; RADIOPHARMACEUTICAL AGENT; SUNITINIB; TRACER; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; CARBON; CHOLINE; DIAGNOSTIC AGENT; METHIONINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; MALE; MOLECULAR IMAGING; MOLECULAR THERAPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; CASE REPORT; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; NEOPLASM; SCINTISCANNING;

AGED; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; CHOLINE; CLINICAL TRIALS AS TOPIC; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METHIONINE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 54849188700     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000026     Document Type: Article

References (69)

1. Ozols RF, Herbst RS, Colson YL, et al: Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 25: 146-162, 2007.
2. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
3. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759, 2007.
4. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxy-glucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782, 1999.
5. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 347: 472-480, 2002.
6. Van Den Abbeele AD and Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumours (GISTs). Eur J Cancer 3 (Suppl 5): 60-65, 2002.
7. Antoch G, Kanja J, Bauer S, et al: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumours. J Clin Med 45: 357-365, 2004.
8. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39: 2012-2020, 2003.
9. Demetri GD, van Osteroom AT, Garret CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006.
10. Goshen E, Davidson T, Zwas ST and Aderka D: PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 5: 37-43, 2006.
11. Willet CG, Duda DG, Di Tomaso E, et al: Complete pathological response to bevacizumab and chemoradiotherapy in advanced rectal cancer. Nat Clin Pract Oncol 4: 316-321, 2007.
12. Kawada K, Murakami K, Sato T, et al: Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol 37: 44-48, 2007.
13. Su H, Bodenstein C, Dumont R, et al: Monitoring glucose utilization by positron emission tomography for prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12: 5659-5667, 2006.
14. Dorow DS, Cullicane C, Conus N, et al: Multitracer small-animal PET imaging of the tumor response to the novel pan-Erb-B inhibitor. Eur J Nucl Med Mol Imaging 33: 441-452, 2006.
15. Sunaga N, Oriuchi N, Kaira K, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59: 203-210, 2008.
16. Fabio DF, Pinto C, Rojas Llimpe FL, et al: The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 10: 221-227, 2007.
17. Pantaleo, MA, Nannini M, Maleddu A, et al: Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 34: 1510-1511, 2007.
18. Majhail NS, Urbain JL, Albani JM, et al: F-18 fluorodeoxy-glucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2: 3995-4000, 2003.
19. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
20. Van den Abbeele AD, Melenevsky Y, de Vries D, et al: FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate. Eur J Cancer Suppl 3: 202, 2005.
21. De Mulder PH, Roigas J, Gillessen S, et al: A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24: 223s, 2006.
22. George S, Casali PG, Blay J, et al: Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. J Clin Oncol 24: 527s, 2006.
23. 11C-choline positron emission tomography. Eur Urol 42: 18-23, 2002.
24. 11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 31: 317-324, 2003.
25. Fazio F, Picchio M and Messa C: Is choline the most appropriate tracer for prostate cancer? For. Eur J Nucl Med Mol Imaging 31: 753-756, 2004.
26. Zöphel K and Kotzerke J: Is choline the most appropriate tracer for prostate cancer? Against. Eur J Nucl Med Mol Imaging 31: 756-759, 2004.
27. 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46: 1642-1649, 2005.
28. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74: 214-220, 2005.
29. 11C-choline PET/CT. J Nucl Med 47: 1249-1254, 2006.
30. 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 34: 45-53, 2007.
31. 18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 179: 482-484, 2002.
32. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 169: 1337-1340, 2003.
33. 18F-choline PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33: 1387-1398, 2006.
34. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
35. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
36. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005.
37. Cai W, Chen X: Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Bioscience 12: 4267-4279, 2007.
38. Chen W, Delaloye S, Silverman DH, et al: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714-4721, 2007.
39. De Geus-Oei LF, van Laarhoven HW, Visser EP, et al: Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 19: 348-352, 2008.
40. Davis FG, Kupelian V, Freels S, et al: Prevalence estimates for primary brain tumors in the United States by behaviour and major histology groups. Neuro-Oncology 3: 152-158, 2001.
41. Brown PD, Wald JT, McDermott MW, et al: Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma. Radiographics 23: 1591-1611, 2003.
42. Singhal T, Narayanan TK, Jain V, et al: (11)C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10: 1-18, 2008.
43. Hustinx R, Pourdehnad M, Kaschten B and Alavi A: PET imaging for differentiating recurrent brain tumours from radiation necrosis. Radiol Clin North Am 43: 35-47, 2005.
44. Wong TZ, Van der Westhuizen GJ and Coleman RE: Positron emission tomography imaging of brain tumours. Neuroimaging Clin N Am 12: 615-626, 2002.
45. Kondziolka D, Lunsford LD and Martinez AJ: Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 79: 533-536, 1993.
46. Gumprecht H, Grosu AL, Souvatsoqlou M, et al: 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 68: 19-23, 2007.
47. Herholz K, Hölzer T, Bauer B, et al: 11-C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50: 1316-1322, 1998.
48. Chung JK, Kim YK, Kim SK, et al: Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29: 176-182, 2002.
49. Braun V, Dempf S, Weller R et al: Cranial neuronavigation with direct integration of (11)C methionine positron emission tomography (PET) data - results of a pilot study in 32 surgical cases. Acta Neurochir 144: 777-782, 2002.
50. Huang MC, Shih MH, Chung WY, et al: Malignancy of intra-cerebral lesions evaluated with 11C-methionine-PET. J Clin Neurosci 12: 775-780, 2005.
51. Kim S, Chung JK, Im SH, et al: 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32: 52-59, 2005.
52. Di Chiro G: Positron emission tomography using [18F] fluorodeoxyglucose in brain tumours. A powerful diagnostic and prognostic tool. Invest Radiol 22: 360-371, 1987.
53. Padma MV, Said S, Jacobs M, et al: Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64: 227-237, 2003.
54. Galldiks N, Kracht LW, Burghaus L, et al: Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33: 516-524, 2006.
55. Tang BN, Sadeghi N, Branle F, De Witte O, Wilker D, Goldman S: Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 71: 161-168, 2005.
56. Herholz K, Kracht LW and Heiss WD: Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 13: 268-271, 2003.
57. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22: 133-142, 2004.
58. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887, 2005.
59. Dresemann G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16: 1702-1708, 2005.
60. Prasad V, Fetscher S and Baum RP: Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view. J Pharm Pharmaceut Sci 10: s321-s337, 2007.
61. Vinik AI, Woltering EA, O'Dorisio TM et al: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. Inter Science Institute, USA, 2006.
62. Rufini V, Calcagni ML and Baum RP: Imaging of neuroendocrine tumors. Semin Nucl Med 36: 228-247, 2006.
63. Wild D, Schmitt JS, Ginj M, et al: DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2,3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30: 1338-1347, 2003.
64. Baum RP, Niesen A, Leonhardi J, et al: Receptor PET/CT imaging of neuroendocrine tumors using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-NaI3-octreotide (DOTA-NOC): clinical results in 327 patients. Eur J Nucl Med Mol 32 (Suppl 1): 54-55, 2005.
65. Eriksson B, Bergström M, Orlefors H, et al: Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 44: 68-76, 2000.
66. Pasquali C, Rubello D, Sperti C, et al: Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22: 589-592, 1998.
67. Belhocine T, Foidart J, Rigo P, et al: Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 23: 727-374, 2002.
68. Oberg K and Eriksson B: Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid. Best Pract Res Clin Endocrinol Metab 19: 265-276, 2005.
69. Mignon M: Natural history of neuroendocrine enteropancreatic tumours. Digestion 62 (Suppl 1): 51-58, 2000.